We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cardiol Therapeutics Inc (CRDL) COM NPV CL A

Sell:2.50 CAD Buy:2.53 CAD Change: 0.05 CAD (2.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:2.50 CAD
Buy:2.53 CAD
Change: 0.05 CAD (2.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:2.50 CAD
Buy:2.53 CAD
Change: 0.05 CAD (2.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

Contact details

Address:
602-2265 Upper Middle Road East
OAKVILLE
L6H 0G5
Canada
Telephone:
+1 (289) 9100850
Website:
https://www.cardiolrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRDL
ISIN:
CA14161Y2006
Market cap:
169.57 million CAD
Shares in issue:
68.28 million
Sector:
Pharmaceuticals
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • David Elsley
    President, Chief Executive Officer, Director
  • Christopher Waddick
    Chief Financial Officer, Corporate Secretary, Director
  • Bernard Lim
    Chief Operating Officer
  • Andrew Hamer
    Chief Medical Officer, Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.